IDH1 and central nervous system cancer: Due to the histopathological heterogeneity of gliomas, RNA-seq data of glioma samples from three independent databases were analyzed according to WHO guidelines, and the analysis included IDH mutation status, 1p/19q co-deletion status, and MGMT promoter status.